Anti-cancer Potential of Bioactive Compounds from Moringa oleifera against PARK2 in Oral Cancer protein: In silico Approach

Anti-cancer Potential of Bioactive Compounds from Moringa oleifera

Abstract

Background: Globally, oral cancer (OC) is one of the most common cancers and it is the second highest incidence in India. Medicinal plants are well known anticancer therapeutic agents since ages and considered alternative treatment of cancer diseases. Moringa oleifera, the most crucial medicinal plant contains a vast number of potential anti-cancer bioactive compounds. Objective: The aim of the  current study is to investigate the therapeutic potential of five bioactive compounds kaempferol, niazimicin, niazinin, O-ethyl-4-(alpha-l-rhamnosyloxy) benzyl carbamate and quercetin of Moringa oleifera target PARK2 against OC proliferation via in silico study. Methodology: In silico approach via ADME/ProTox-II tools and molecular docking analysis have assessed to find binding affinity between PARK2 and Moringa oleifera selected compounds. Results: Our finding revealed that Kaempferol, bioactive compounds of Moringa oleifera shows Lipinski's Five Rules and is non-toxic to the liver. Besides, it also displays higher binding affinity -7.2kcal/mol and a lower binding energy followed by five selected compounds and also from 5-Flurouracil with the PARK2 interaction. Conclusion: The study provided insight into Kaempferol's possibilities of success as drug discovery candidates in the face of PARK2-related OC regulation. Thus, future in vitro, in vivo, and clinical studies are required to corroborate our findings.